Answers are grounded in this paper and cite their sources.
The 5th edition WHO Classification of Breast Tumours (2019) has introduced changes to our practices. Highlights are presented below, with a focus on modifications to morphological subtype categorization. In addition, we summarize important updates to ER and PR testing made in the 2020 ASCO/CAP guidelines, and briefly discuss PD-L1 and Ki-67 testing in breast cancer.
No takes yet. Share an insight, caveat, or question.
Muller et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: